Apogee Therapeutics, Inc. Common Stock (APGE) Stock
APGE is no longer traded. Apogee Therapeutics, Inc. Common Stock was acquired by AbbVie (ABBV) in August 2026.
Prices on this page are historical; the last trade was August 31, 2026 at $135.08.
See AbbVie (ABBV) stock →Apogee Therapeutics, Inc. Common Stock stock price history
APGE final trading statistics
- Final close
- $135.08
- Final trading day
- Aug 31, 2026
- Market cap at delisting
- $8.40B
- Shares outstanding
- 62.20M
- Final 52-week range
- $35.39 – $135.08
- Avg. volume (final 3 mo.)
- 2,729,936
- All-time high (split-adj.)
- $135.08 · Aug 2026
- All-time low (split-adj.)
- $15.00 · Oct 2023
- Return since IPO
- +694.6%
- Beta
- 0.33
- Book value / share
- $15.91
- Price / book
- 8.49
Apogee Therapeutics, Inc. Common Stock annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $0.00 | -$255.8M | -$4.22 |
| FY2024 | $0.00 | -$182.1M | -$3.28 |
| FY2023 | $0.00 | -$84.0M | -$6.99 |
| FY2022 | $0.00 | -$39.8M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.
Apogee Therapeutics, Inc. Common Stock stock FAQ
What happened to Apogee Therapeutics, Inc. Common Stock stock?
Apogee Therapeutics, Inc. Common Stock was acquired by AbbVie (ABBV) in August 2026. APGE stock stopped trading on the Nasdaq, with a final close of $135.08 on August 31, 2026.
Is APGE stock still trading?
No. APGE was delisted from the Nasdaq in August 2026 and no longer trades on a U.S. exchange.
What was the last price of APGE stock?
APGE closed at $135.08 on its final trading day, August 31, 2026, for a market value of about $8.40B.
What were Apogee Therapeutics, Inc. Common Stock's revenue and earnings in its last full fiscal year?
Apogee Therapeutics, Inc. Common Stock reported revenue of $0.00 and net income of -$255.8M in fiscal 2025, its last full year as a public company.
When did Apogee Therapeutics, Inc. Common Stock go public?
Apogee Therapeutics, Inc. Common Stock stock began trading on July 14, 2023.